Pfizer Inc. (NYSE:PFE) Shares Sold by Keybank National Association OH

Keybank National Association OH lessened its position in Pfizer Inc. (NYSE:PFE) by 4.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,609,917 shares of the biopharmaceutical company’s stock after selling 75,877 shares during the period. Keybank National Association OH’s holdings in Pfizer were worth $42,711,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of PFE. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer during the fourth quarter valued at $26,000. Gladius Capital Management LP grew its stake in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares in the last quarter. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer in the fourth quarter valued at about $28,000. Noble Wealth Management PBC purchased a new position in Pfizer in the fourth quarter valued at about $31,000. Finally, Teachers Insurance & Annuity Association of America purchased a new position in Pfizer in the third quarter valued at about $35,000. Institutional investors own 68.36% of the company’s stock.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is owned by insiders.

Pfizer Stock Down 0.8 %

PFE opened at $26.21 on Tuesday. The company has a fifty day moving average price of $26.34 and a 200-day moving average price of $27.30. The firm has a market capitalization of $148.53 billion, a P/E ratio of 18.59, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the previous year, the business earned $0.10 earnings per share. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.56%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is 121.99%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on PFE shares. UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Guggenheim reaffirmed a “buy” rating and issued a $33.00 price target on shares of Pfizer in a report on Monday, February 10th. Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Truist Financial decreased their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Finally, Bank of America reiterated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.